F076 Melanoma in Situ: Ongoing Controversies and New Insights
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
The primary clinical significance of melanocytic neoplasms lies in preventing deaths from melanoma through early detection, known as 'secondary prevention'. Achieving secondary prevention of melanoma requires distinguishing benign lesions from lesions likely to progress to metastatic disease without intervention and, b. identifying the latter lesions early enough to prevent progression. In this session, we delve into several challenging and contentious topics related to identifying and managing borderline melanocytic neoplasms with a focus on melanoma in situ.. We will explore: a. the clinical and pathological challenges in classifying MIS, b. the risks and benefits of intensifying detection efforts for MIS, and c. the roles of emerging technologies, including AI and molecular profiling, in aiding detection and classification.
LEARNING OBJECTIVES
Discuss the significance of melanoma in situ
Discuss the challenges and opportunities in classifying MIS and applying AI to melanoma diagnosis
Discuss the changing landscape of melanoma education and screening
SCHEDULE
10:30 PM
Introduction: Is Melanoma in Situ Cancer?
Allan C. Halpern, MD, FAAD
10:50 PM
MIS and Public Health: Implications for Screening and Education in Low Mortality Populations.
Collin Costello, MD, FAAD
11:10 PM
Molecular Profiling at the MIS borderline: Boon or Bane for Melanoma Diagnosis?
Shirin Bajaj, MD, FAAD
11:30 PM
Balancing Act: Integrating MIS with Borderline Lesions in MPath II.
Pedram Gerami, MD
11:50 PM
AI Training and Application at the MIS Boundary.
Laura K. Ferris, MD, PhD, FAAD
12:10 AM
Panel Discussion
SPEAKERS
Shirin Bajaj, MD, FAAD
Collin Costello, MD, FAAD
Laura K. Ferris, MD, PhD, FAAD
Allan C. Halpern, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Shirin Bajaj, MD, FAAD
No financial relationships exist with ineligible companies.
Collin Costello, MD, FAAD
DeepX Health – Investigator(Grants/Research Funding); Melanoma Research Alliance – Investigator(Grants/Research Funding); Merck – Investigator(Grants/Research Funding);
Laura K. Ferris, MD, PhD, FAAD
AbbVie – Consultant(Honoraria), Investigator(Other Financial Benefit); Acelyrin – Investigator(Grants/Research Funding); Amgen – Investigator(Other Financial Benefit); Arcutis, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Other Financial Benefit), Speaker(Honoraria); Bristol-Myers Squibb – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Cara Therapeutics – Consultant(Honoraria), Investigator(Grants/Research Funding); Castle Biosciences, Inc – Investigator(Other Financial Benefit); Dermavant Sciences – Consultant(Honoraria), Investigator(Grants/Research Funding); DermTech International – Consultant(Honoraria), Investigator(Other Financial Benefit); Eli Lilly and Company – Investigator(Other Financial Benefit); Galderma – Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Consultant(Honoraria); Janssen Research & Development, LLC – Investigator(Other Financial Benefit); Leo Pharma Inc – Consultant(Honoraria); LEO Pharma, US – Investigator(Other Financial Benefit); Moberg Pharma North America LLC – Investigator(Grants/Research Funding); Novartis – Investigator(Other Financial Benefit); Pfizer Inc. – Data Safety Monitoring Board(Honoraria), Investigator(Grants/Research Funding); Regeneron – Consultant(Honoraria), Investigator(Other Financial Benefit); skinanalytics – Investigator(Grants/Research Funding); UCB – Investigator(Grants/Research Funding); Verrica Pharmaceuticals Inc – Investigator(Grants/Research Funding);
Allan C. Halpern, MD, FAAD
Canfield Scientific, Inc. – Consultant(Other Financial Benefit); SciBASE – Consultant(Other Financial Benefit); SpotDoc – Founder(Other Financial Benefit);